Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sunstar: Consolidated Sales Down 3.8%
December 16, 2002
- OTC NEWS IN BRIEF
December 16, 2002
- EPS: Large Increases in Both Sales, Profits
December 16, 2002
- MEDICAL DEVICE NEWS IN BRIEF
December 16, 2002
- Nissan Chemical: Drug Sales Down 31.4% to \718 Mil.
December 16, 2002
- WORLD NEWS IN BRIEF
December 16, 2002
- Morishita Jintan: Sales Down 26.4% to \5.3 Bil.
December 16, 2002
- BULLETIN
December 16, 2002
- Biofermin: Sales Up 0.4% to \3,513 Mil.
December 16, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 16, 2002
- JCR: Withdrawal of Application for IFN-a Affects Business Results
December 16, 2002
- Meet the Leaders (13)
December 16, 2002
- Nichiban: Profits Rise Despite 2.3% Decline in Sales
December 16, 2002
- Sanofi-Synthelabo to Further Boost Investment in Japan in 2003
December 16, 2002
- Sanus, Honma Toho: Return to the Black with Improved Profitability
December 16, 2002
- Bayer Biological Products to License IVIG Production Technology to JRC
December 16, 2002
- Tax Deduction from Total Clinical Research Cost to Be Allowed
December 16, 2002
- Novartis Aims For 10% Statin Market Share for Lochol
December 16, 2002
- Ando Chemical Works: Sales Post 6% Increase
December 16, 2002
- REGULATORY NEWS IN BRIEF
December 16, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…